Management of moderate to severe plaque psoriasis with biologic therapy.
David M
DM
Pariser
D000077944:Alefacept; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000938:Antigen-Presenting Cells / Q000276:immunology; D001688:Biological Products / Q000008:administration & dosage* / Q000145:classification / Q000493:pharmacokinetics; D001691:Biological Therapy / Q000639:trends*; D002986:Clinical Trials as Topic; D019468:Disease Management; D016503:Drug Delivery Systems; D006801:Humans; D000069285:Infliximab; D011565:Psoriasis / Q000276:immunology / Q000503:physiopathology / Q000517:prevention & control / Q000628:therapy*; D011993:Recombinant Fusion Proteins / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use; D013601:T-Lymphocytes / Q000187:drug effects; D014481:United States
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D001688:Biological Products; D011993:Recombinant Fusion Proteins; D000069285:Infliximab; D000077944:Alefacept; C472181:efalizumab